Neurocrine Biosciences Q4 earnings: EPS $1.88 missed by -10.05%, revenue up $177.80M YoY. Details on Benzinga.com.
Neurocrine Biosciences (NASDAQ: NBIX) released its Q4 financial results on February 11, 2026, at 04:01 PM. The earnings report showed that the company fell short of estimated earnings by -10.05%, with an EPS of $1.88 compared to the expected $2.09. Revenue saw an increase of $177.80 million compared to the previous year. In terms of past earnings performance, the company surpassed expectations on EPS. For more detailed information, the full story can be found on Benzinga.com.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments